STERIS (STE) investors have had quite the week. The U.S. Commerce Department’s national security investigation into imported medical devices sent shockwaves through the sector, sparking questions about future tariffs and supply chain impacts. For a company as deeply embedded in the medical equipment space as STERIS, the news has pushed both risks and opportunities into sharper focus, making it a keen moment for current and prospective shareholders to reassess their outlook. Despite the regulatory cloud hanging over the industry, STERIS’ shares have surged over 10% recently and are trading at yearly highs. That move stands out in a sector generally rattled by tariff talk and policy uncertainty. With solid full-year gains and a strong multi-year run, momentum behind STERIS looks persistent, boosted by growth in its Healthcare and Applied Sterilization Technologies segments even as competitors wobble. With a backdrop of higher share prices and a cloudier policy environment, the question remains whether STERIS is set for further gains, or if the market has already factored in those brighter earnings prospects.

Most Popular Narrative: 8.6% Undervalued

According to the most widely tracked narrative, STERIS shares are currently considered undervalued based on expected future earnings growth and margin expansion. The consensus among analysts suggests that at the current discount rate, the fair value is higher than today's share price.

Continued expansion of STERIS's consumables and services segments, with high recurring revenue and margin visibility, positions the company to benefit from increasing healthcare expenditures and adoption of best-practice infection control standards. This supports both revenue and margin expansion. Recent resurgence in capital equipment purchases for pharmaceutical and life sciences manufacturing, as well as healthcare facility expansion (including ambulatory surgery centers), reflects secular infrastructure investment trends globally. These factors should contribute to top-line growth and improved operating leverage.

Want a behind-the-scenes look at what is powering this bullish valuation? The story hinges on robust projections for both earnings and margins, shaped by huge demand trends in healthcare and fresh investment in critical infrastructure. Curious which specific financial assumptions are tempting analysts to raise their targets? Discover the details that could explain today's optimism in the full narrative.

Result: Fair Value of $272.38 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, risks remain, including tariff hikes that could pressure margins and reimbursement changes that might squeeze future revenue growth.

Find out about the key risks to this STERIS narrative.

Another View: Are Shares Actually Expensive?

Looking at a different yardstick, STERIS appears expensive compared to others in its sector based on its current earnings multiple. This method questions whether investor optimism is already fully baked in. Could enthusiasm be running ahead of value?

See what the numbers say about this price — find out in our valuation breakdown.

Stay updated when valuation signals shift by adding STERIS to your watchlist or portfolio. Alternatively, explore our screener to discover other companies that fit your criteria.

Build Your Own STERIS Narrative

If you see things differently or want to dig into the data yourself, crafting your own thesis takes just a few minutes. Do it your way.

A good starting point is our analysis highlighting 2 key rewards investors are optimistic about regarding STERIS.

Looking for More Investment Ideas?

Smart opportunities are waiting beyond STERIS. Don’t limit your portfolio to just one story. Take your next step by uncovering companies with real potential in today’s market.

• Tap into emerging breakthroughs by targeting next-generation technology companies using the power of quantum computing stocks.
• Secure steady income streams by searching for top picks offering impressive yields through dividend stocks with yields > 3%.
• Zero in on undervalued gems across the market and make your capital work harder with undervalued stocks based on cash flows.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.